{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T11:19:01Z","timestamp":1793272741320,"version":"4.5.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100002332","name":"Semmelweis University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002332","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s11523-026-01230-3","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T06:35:58Z","timestamp":1782714958000},"page":"507-520","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety Differences Between Abiraterone and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-analysis of Real-World Studies"],"prefix":"10.1007","volume":"21","author":[{"given":"Anik\u00f3 Katalin","family":"Valikovics","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e1niel","family":"Bacs\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadeen","family":"Samaien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel Pinto Amorim","family":"das Virgens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogl\u00e1rka","family":"Szentes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gergely","family":"Ag\u00f3cs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Obeidat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Sz\u00e9ll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Hadaschik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Hegyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Nyir\u00e1dy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tibor","family":"Szarvas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"1230_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"1230_CR2","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Guidelines for Patients: Prostate Cancer \u2013 Advanced Stage. Version 2.2025. Published April 16, 2025. https:\/\/www.nccn.org\/patients\/guidelines\/content\/PDF\/prostate-advanced-patient.pdf. Accessed 14 Jan 2026."},{"key":"1230_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12298-3","volume":"24","author":"D Obinata","year":"2024","unstructured":"Obinata D, Takayama K, Lawrence MG, Funakoshi D, Hara M, Niranjan B, et al. Patient-derived castration-resistant prostate cancer model revealed CTBP2 upregulation mediated by OCT1 and androgen receptor. BMC Cancer. 2024;24:554. https:\/\/doi.org\/10.1186\/s12885-024-12298-3.","journal-title":"BMC Cancer"},{"key":"1230_CR4","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.clgc.2019.12.019","volume":"18","author":"DJ George","year":"2020","unstructured":"George DJ, Sartor O, Miller K, Saad F, Tombal B, Kalinovsk\u00fd J, et al. Treatment patterns and outcomes in patients with metastatic castration-resistant prostate cancer in a real-world clinical practice setting in the United States. Clin Genitourin Cancer. 2020;18:284\u201394. https:\/\/doi.org\/10.1016\/j.clgc.2019.12.019.","journal-title":"Clin Genitourin Cancer"},{"key":"1230_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100575","volume":"7","author":"BA Maiorano","year":"2022","unstructured":"Maiorano BA, De Giorgi U, Roviello G, Messina C, Altavilla A, Cattrini C, et al. Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. ESMO Open. 2022;7:100575. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100575.","journal-title":"ESMO Open"},{"key":"1230_CR6","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS De Bono","year":"2011","unstructured":"De Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995\u20132005. https:\/\/doi.org\/10.1056\/NEJMoa1014618.","journal-title":"N Engl J Med"},{"key":"1230_CR7","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin M-E, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1207506.","journal-title":"N Engl J Med"},{"key":"1230_CR8","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","volume":"16","author":"CJ Ryan","year":"2015","unstructured":"Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PFA, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152\u201360. https:\/\/doi.org\/10.1016\/S1470-2045(14)71205-7.","journal-title":"Lancet Oncol"},{"key":"1230_CR9","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.eururo.2016.07.032","volume":"71","author":"TM Beer","year":"2017","unstructured":"Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in men with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study. Eur Urol. 2017;71:151\u20134. https:\/\/doi.org\/10.1016\/j.eururo.2016.07.032.","journal-title":"Eur Urol"},{"key":"1230_CR10","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1177\/1078155219842329","volume":"26","author":"H Lahcene","year":"2020","unstructured":"Lahcene H, Aprikian AG, Vanhuyse M, Hu J, Bladou F, Cury F, et al. Impact of the introduction of novel hormonal agents on metastatic castration-resistant prostate cancer treatment choice. J Oncol Pharm Pract. 2020;26:293\u2013305. https:\/\/doi.org\/10.1177\/1078155219842329.","journal-title":"J Oncol Pharm Pract"},{"key":"1230_CR11","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1016\/S1470-2045(19)30688-6","volume":"20","author":"DJ Khalaf","year":"2019","unstructured":"Khalaf DJ, Annala M, Taavitsainen S, Finch DL, Oja C, Vergidis J, et al. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncol. 2019;20:1730\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(19)30688-6.","journal-title":"Lancet Oncol"},{"key":"1230_CR12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.28444","volume":"7","author":"J La","year":"2024","unstructured":"La J, Wang L, Corrigan JK, Lang D, Lee MH, Do NV, et al. Abiraterone or enzalutamide for patients with metastatic castration-resistant prostate cancer. JAMA Netw Open. 2024;7:e2428444. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.28444.","journal-title":"JAMA Netw Open"},{"key":"1230_CR13","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/s41391-024-00816-0","volume":"27","author":"DJ George","year":"2024","unstructured":"George DJ, Ramaswamy K, Yang H, Liu Q, Zhang A, Greatsinger A, et al. Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-na\u00efve patients with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2024;27:756\u201364. https:\/\/doi.org\/10.1038\/s41391-024-00816-0.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1230_CR14","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1093\/aje\/kwaa190","volume":"190","author":"L-M Scailteux","year":"2021","unstructured":"Scailteux L-M, Campillo-Gimenez B, Kerbrat S, Despas F, Mathieu R, Vincendeau S, et al. Overall survival among chemotherapy-naive patients with castration-resistant prostate cancer under abiraterone versus enzalutamide: a direct comparison based on a 2014\u20132018 French population study (the SPEAR cohort). Am J Epidemiol. 2021;190:413\u201322. https:\/\/doi.org\/10.1093\/aje\/kwaa190.","journal-title":"Am J Epidemiol"},{"key":"1230_CR15","doi-asserted-by":"publisher","first-page":"1491314","DOI":"10.3389\/fonc.2025.1491314","volume":"15","author":"A Aprikian","year":"2025","unstructured":"Aprikian A, Bahl A, Omlin A, Baciarello G, Chakravarty A, Kondaparthi P, et al. Meta-analysis to evaluate the comparative effectiveness of enzalutamide and abiraterone acetate for first-line treatment of metastatic castration-resistant prostate cancer in real-world settings. Front Oncol. 2025;15:1491314. https:\/\/doi.org\/10.3389\/fonc.2025.1491314.","journal-title":"Front Oncol"},{"key":"1230_CR16","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1097\/JCMA.0000000000000353","volume":"83","author":"S-F Wang","year":"2020","unstructured":"Wang S-F, Chen K-H, Wang S-Y, Yarmishyn AA, Lai W-Y, Lin Y-Y, et al. The pharmacological development of direct acting agents for emerging needed therapy against severe acute respiratory syndrome coronavirus-2. J Chin Med Assoc. 2020;83:712\u20138. https:\/\/doi.org\/10.1097\/JCMA.0000000000000353.","journal-title":"J Chin Med Assoc"},{"key":"1230_CR17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/2046-4053-2-4","volume":"2","author":"A Booth","year":"2013","unstructured":"Booth A, Clarke M, Dooley G, Ghersi D, Moher D, Petticrew M, et al. PROSPERO at one year: an evaluation of its utility. Syst Rev. 2013;2:4. https:\/\/doi.org\/10.1186\/2046-4053-2-4.","journal-title":"Syst Rev"},{"key":"1230_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"2021","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. statement: an updated guideline for reporting systematic reviews. BMJ. 2020;2021:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"1230_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"J Higgins","year":"2019","unstructured":"Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic reviews of interventions. 2nd ed. Newark: Wiley, Incorporated; 2019.","edition":"2"},{"key":"1230_CR20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12874-017-0468-4","volume":"18","author":"Z Munn","year":"2018","unstructured":"Munn Z, Stern C, Aromataris E, Lockwood C, Jordan Z. What kind of systematic review should I conduct? A proposed typology and guidance for systematic reviewers in the medical and health sciences. BMC Med Res Methodol. 2018;18:5. https:\/\/doi.org\/10.1186\/s12874-017-0468-4.","journal-title":"BMC Med Res Methodol"},{"key":"1230_CR21","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/jrsm.1563","volume":"13","author":"NR Haddaway","year":"2022","unstructured":"Haddaway NR, Grainger MJ, Gray CT. Citationchaser: A tool for transparent and efficient forward and backward citation chasing in systematic searching. Res Synth Methods. 2022;13:533\u201345. https:\/\/doi.org\/10.1002\/jrsm.1563.","journal-title":"Res Synth Methods"},{"key":"1230_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016:355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919.","journal-title":"BMJ"},{"key":"1230_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019:366:l4898.\u00a0https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"1230_CR24","unstructured":"Oxford Centre for Evidence-Based Medicine. OCEBM levels of evidence. University of Oxford; 2011 [cited 2025 Oct 12]. Available from: https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence."},{"key":"1230_CR25","unstructured":"Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle\u2013Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute; 2011 [cited 2025 Oct 12]. Available from: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"1230_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4008","author":"BJ Shea","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017:358:j4008.\u00a0https:\/\/doi.org\/10.1136\/bmj.j4008.","journal-title":"BMJ"},{"key":"1230_CR27","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16. https:\/\/doi.org\/10.1186\/1745-6215-8-16.","journal-title":"Trials"},{"key":"1230_CR28","doi-asserted-by":"publisher","DOI":"10.1201\/9781003107347","volume-title":"Doing meta-analysis with R: a hands-on guide","author":"M Harrer","year":"2021","unstructured":"Harrer M, Cuijpers P, Furukawa TA, Ebert DD. Doing meta-analysis with R: a hands-on guide. 1st ed. Boca Raton: Chapman and Hall\/CRC; 2021. https:\/\/doi.org\/10.1201\/9781003107347.","edition":"1st ed"},{"key":"1230_CR29","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1164","volume":"7","author":"AA Veroniki","year":"2016","unstructured":"Veroniki AA, Jackson D, Viechtbauer W, Bender R, Bowden J, Knapp G, et al. Methods to estimate the between-study variance and its uncertainty in meta-analysis. Res Synth Methods. 2016;7:55\u201379. https:\/\/doi.org\/10.1002\/jrsm.1164.","journal-title":"Res Synth Methods"},{"key":"1230_CR30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1471-2288-14-25","volume":"14","author":"J IntHout","year":"2014","unstructured":"IntHout J, Ioannidis JP, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. 2014;14:25. https:\/\/doi.org\/10.1186\/1471-2288-14-25.","journal-title":"BMC Med Res Methodol"},{"key":"1230_CR31","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JPT Higgins","year":"2002","unstructured":"Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539\u201358. https:\/\/doi.org\/10.1002\/sim.1186.","journal-title":"Stat Med"},{"key":"1230_CR32","unstructured":"Rohatgi A. WebPlotDigitizer [computer software]. Version 4.8. 2022 [cited 2026 Jan 14]. Available from: https:\/\/automeris.io\/WebPlotDigitizer."},{"key":"1230_CR33","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","volume":"21","author":"N Liu","year":"2021","unstructured":"Liu N, Zhou Y, Lee JJ. IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2021;21:111. https:\/\/doi.org\/10.1186\/s12874-021-01308-8.","journal-title":"BMC Med Res Methodol"},{"key":"1230_CR34","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1002\/sim.6111","volume":"33","author":"C Combescure","year":"2014","unstructured":"Combescure C, Foucher Y, Jackson D. Meta-analysis of single-arm survival studies: a distribution-free approach for estimating summary survival curves with random effects. Stat Med. 2014;33:2521\u201337. https:\/\/doi.org\/10.1002\/sim.6111.","journal-title":"Stat Med"},{"key":"1230_CR35","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing; 2024 [cited 2026 Jan 14]. Available from: https:\/\/www.r-project.org\/."},{"key":"1230_CR36","unstructured":"Schwarzer G. meta: general package for meta-analysis [computer software]. 2022 [cited 2026 Jan 14]. Available from: https:\/\/github.com\/guido-s\/meta\/."},{"key":"1230_CR37","unstructured":"Cuijpers P, Furukawa T, Ebert DD. dmetar: companion R package for the guide doing meta-analysis in R [computer software]. 2023 [cited 2026 Jan 14]. Available from: https:\/\/dmetar.protectlab.org\/."},{"key":"1230_CR38","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/s41391-021-00318-3","volume":"24","author":"ST Tagawa","year":"2021","unstructured":"Tagawa ST, Ramaswamy K, Huang A, Mardekian J, Schultz NM, Wang L, et al. Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate. Prostate Cancer Prostatic Dis. 2021;24:1032\u201340. https:\/\/doi.org\/10.1038\/s41391-021-00318-3.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1230_CR39","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1186\/s12885-023-10885-4","volume":"23","author":"C-S Tseng","year":"2023","unstructured":"Tseng C-S, Yang J-H, Huang S-W, Wang Y-J, Chen C-H, Pu Y-S, et al. Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer. BMC Cancer. 2023;23:568. https:\/\/doi.org\/10.1186\/s12885-023-10885-4.","journal-title":"BMC Cancer"},{"key":"1230_CR40","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41391-022-00588-5","volume":"26","author":"MW Schoen","year":"2023","unstructured":"Schoen MW, Carson KR, Eisen SA, Bennett CL, Luo S, Reimers MA, et al. Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases. Prostate Cancer Prostatic Dis. 2023;26:743\u201350. https:\/\/doi.org\/10.1038\/s41391-022-00588-5.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1230_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.656146","volume":"11","author":"R Raju","year":"2021","unstructured":"Raju R, Sahu A, Klevansky M, Torres J. Real-world data on outcomes in metastatic castrate-resistant prostate cancer patients treated with abiraterone or enzalutamide: a regional experience. Front Oncol. 2021;11:656146. https:\/\/doi.org\/10.3389\/fonc.2021.656146.","journal-title":"Front Oncol"},{"key":"1230_CR42","doi-asserted-by":"publisher","first-page":"1108937","DOI":"10.3389\/fonc.2023.1108937","volume":"13","author":"D Sigorski","year":"2023","unstructured":"Sigorski D, Wilk M, Gawlik-Urban A, Sa\u0142ek-Za\u0144 A, Kiszka J, Malik M, et al. Real-life data of abiraterone acetate and enzalutamide treatment in post-chemotherapy metastatic castration-resistant prostate cancer in Poland. Front Oncol. 2023;13:1108937. https:\/\/doi.org\/10.3389\/fonc.2023.1108937.","journal-title":"Front Oncol"},{"key":"1230_CR43","doi-asserted-by":"publisher","first-page":"7","DOI":"10.37047\/jos.2021-85879","volume":"8","author":"\u00d6N Sever","year":"2022","unstructured":"Sever \u00d6N, Bah\u00e7eci\u0307 A, Ye\u015fi\u0307L \u00c7inkir H, Yildirim M. Our experience with abiraterone and enzalutamide in the treatment of metastatic castration-resistant prostate cancer: Retrospective Real-Life Data. J Oncol Sci. 2022;8:7\u201313. https:\/\/doi.org\/10.37047\/jos.2021-85879.","journal-title":"J Oncol Sci"},{"key":"1230_CR44","doi-asserted-by":"publisher","first-page":"393","DOI":"10.4081\/aiua.2021.4.393","volume":"93","author":"RS Jarimba","year":"2021","unstructured":"Jarimba RS, Eliseu MN, Pedroso Lima J, Quaresma V, Moreira P, Coelho Nunes P, et al. Novel hormonal agents for metastatic castration-resistant prostate cancer: comparing outcomes. A single-center retrospective study. Arch Ital Urol Androl. 2021;93:393\u20138. https:\/\/doi.org\/10.4081\/aiua.2021.4.393.","journal-title":"Arch Ital Urol Androl"},{"key":"1230_CR45","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1007\/s00345-019-02974-6","volume":"38","author":"M Ferriero","year":"2020","unstructured":"Ferriero M, Mastroianni R, De Nunzio C, Cindolo L, Calabr\u00f2 F, Tema G, et al. Managing lines of therapy in castration-resistant prostate cancer: real-life snapshot from a multicenter cohort. World J Urol. 2020;38:1757\u201364. https:\/\/doi.org\/10.1007\/s00345-019-02974-6.","journal-title":"World J Urol"},{"key":"1230_CR46","doi-asserted-by":"publisher","unstructured":"Alkan A, G\u00fc\u00e7 ZG, G\u00fcrb\u00fcz M, \u00d6zg\u00fcn G, De\u011firmencio\u011flu S, Do\u011fan M, et al. Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (\u226575) patients. J Men\u2019s Health. 2021;17(4):128-34. https:\/\/doi.org\/10.31083\/jomh.2021.041.","DOI":"10.31083\/jomh.2021.041"},{"key":"1230_CR47","doi-asserted-by":"publisher","first-page":"14131","DOI":"10.1038\/s41598-021-93659-x","volume":"11","author":"A Demirci","year":"2021","unstructured":"Demirci A, Bilir C, G\u00fclba\u011fc\u0131 B, Hac\u0131bekiro\u011flu \u0130, Bayo\u011flu \u0130V, Bilgetekin \u0130, et al. Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer. Sci Rep. 2021;11:14131. https:\/\/doi.org\/10.1038\/s41598-021-93659-x.","journal-title":"Sci Rep"},{"key":"1230_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.822375","volume":"12","author":"P-Y Li","year":"2022","unstructured":"Li P-Y, Lu Y-H, Chen C-Y. Comparative effectiveness of abiraterone and enzalutamide in patients with metastatic castration-resistant prostate cancer in Taiwan. Front Oncol. 2022;12:822375. https:\/\/doi.org\/10.3389\/fonc.2022.822375.","journal-title":"Front Oncol"},{"key":"1230_CR49","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2024.1763","author":"MY Soomro","year":"2024","unstructured":"Soomro MY, Khan SR, Ishfaq H, Ali I, Samar MR, Hameed A, et al. Clinical outcomes in metastatic prostate adenocarcinoma treated with abiraterone and enzalutamide. Ecancer. 2024;18:1763. https:\/\/doi.org\/10.3332\/ecancer.2024.1763.","journal-title":"Ecancer"},{"key":"1230_CR50","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.42093","volume":"5","author":"M Marar","year":"2022","unstructured":"Marar M, Long Q, Mamtani R, Narayan V, Vapiwala N, Parikh RB. Outcomes among African American and non-Hispanic white men with metastatic castration-resistant prostate cancer with first-line abiraterone. JAMA Netw Open. 2022;5:e2142093. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.42093.","journal-title":"JAMA Netw Open"},{"key":"1230_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.669236","volume":"12","author":"Y-T Lin","year":"2021","unstructured":"Lin Y-T, Huang Y-C, Liu C-K, Lee T-S, Chen M, Chien Y-N. Treatment-emergent co-morbidities and survival in patients with metastatic castration-resistant prostate cancer receiving abiraterone or enzalutamide. Front Pharmacol. 2021;12:669236. https:\/\/doi.org\/10.3389\/fphar.2021.669236.","journal-title":"Front Pharmacol"},{"key":"1230_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2023.101520","volume":"14","author":"ES Deol","year":"2023","unstructured":"Deol ES, Sanfilippo KM, Luo S, Fiala MA, Wildes T, Mian H, et al. Frailty and survival among veterans treated with abiraterone or enzalutamide for metastatic castration-resistant prostate cancer. J Geriatr Oncol. 2023;14:101520. https:\/\/doi.org\/10.1016\/j.jgo.2023.101520.","journal-title":"J Geriatr Oncol."},{"key":"1230_CR53","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/s41391-023-00757-0","volume":"27","author":"YHA Lee","year":"2024","unstructured":"Lee YHA, Hui JMH, Leung CH, Tsang CTW, Hui K, Tang P, et al. Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: a retrospective cohort study. Prostate Cancer Prostatic Dis. 2024;27:776\u201382. https:\/\/doi.org\/10.1038\/s41391-023-00757-0.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1230_CR54","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s11523-020-00720-2","volume":"15","author":"S Chowdhury","year":"2020","unstructured":"Chowdhury S, Bjartell A, Lumen N, Maroto P, Paiss T, Gomez-Veiga F, et al. Real-world outcomes in first-line treatment of metastatic castration-resistant prostate cancer: Prostate Cancer Registry. Targ Oncol. 2020;15:301\u201315. https:\/\/doi.org\/10.1007\/s11523-020-00720-2.","journal-title":"Targ Oncol"},{"key":"1230_CR55","doi-asserted-by":"publisher","first-page":"175883592311561","DOI":"10.1177\/17588359231156147","volume":"15","author":"PV Nuzzo","year":"2023","unstructured":"Nuzzo PV, Ravera F, Saieva C, Zanardi E, Fotia G, Malgeri A, et al. Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer. Ther Adv Med Oncol. 2023;15:17588359231156148. https:\/\/doi.org\/10.1177\/17588359231156147.","journal-title":"Ther Adv Med Oncol"},{"key":"1230_CR56","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/ijc.34348","volume":"152","author":"H Chen","year":"2023","unstructured":"Chen H, Su P, Wang Y, Chang K, Su Y, Chang P, et al. Long-term use and risk of major adverse cardiac events: Comparing enzalutamide and abiraterone in chemotherapy-na\u00efve patients with metastatic castration-resistant prostate cancer. Int J Cancer. 2023;152:1191\u2013201. https:\/\/doi.org\/10.1002\/ijc.34348.","journal-title":"Int J Cancer"},{"key":"1230_CR57","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/bco2.129","volume":"3","author":"A Anton","year":"2022","unstructured":"Anton A, Pillai S, Semira MC, Wong S, Shapiro J, Weickhardt A, et al. Real-world first-line systemic therapy patterns in metastatic castration-resistant prostate cancer. BJUI Compass. 2022;3:205\u201313. https:\/\/doi.org\/10.1002\/bco2.129.","journal-title":"BJUI Compass"},{"key":"1230_CR58","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ejca.2021.05.003","volume":"152","author":"M Soleimani","year":"2021","unstructured":"Soleimani M, Zou K, Sunderland K, Struss W, Eigl BJ, Nappi L, et al. Effectiveness of first-line abiraterone versus enzalutamide among patients \u226580 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score\u2013weighted comparative cohort study. Eur J Cancer. 2021;152:215\u201322. https:\/\/doi.org\/10.1016\/j.ejca.2021.05.003.","journal-title":"Eur J Cancer"},{"key":"1230_CR59","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/pds.4998","volume":"29","author":"K Baillie","year":"2020","unstructured":"Baillie K, Mueller T, Pan J, Laskey J, Bennie M, Crearie C, et al. Use of record linkage to evaluate treatment outcomes and trial eligibility in a real-world metastatic prostate cancer population in Scotland. Pharmacoepidemiol Drug Saf. 2020;29:653\u201363. https:\/\/doi.org\/10.1002\/pds.4998.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1230_CR60","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/bco2.11","volume":"1","author":"P Das","year":"2020","unstructured":"Das P, Taylor S, Price J, Jones M, Martin-Fernandez C, Ali A, et al. Abiraterone acetate plus prednisone\/prednisolone compared with enzalutamide in metastatic castration resistant prostate cancer before or after chemotherapy: A retrospective study of real-world data (ACES). BJUI Compass. 2020;1:21\u201331. https:\/\/doi.org\/10.1002\/bco2.11.","journal-title":"BJUI Compass"},{"key":"1230_CR61","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.clgc.2016.06.010","volume":"15","author":"H Miyake","year":"2017","unstructured":"Miyake H, Hara T, Terakawa T, Ozono S, Fujisawa M. Comparative assessment of clinical outcomes between abiraterone acetate and enzalutamide in patients with docetaxel-naive metastatic castration-resistant prostate cancer: experience in real-world clinical practice in Japan. Clin Genitourin Cancer. 2017;15:313\u20139. https:\/\/doi.org\/10.1016\/j.clgc.2016.06.010.","journal-title":"Clin Genitourin Cancer"},{"key":"1230_CR62","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s10147-023-02441-8","volume":"29","author":"T Shimomura","year":"2024","unstructured":"Shimomura T, Mori K, Yasue K, Matsukawa A, Fukuokaya W, Yanagisawa T, et al. Survival outcome of chemotherapy-na\u00efve castration-resistant prostate cancer treated with new-generation androgen receptor axis-targeted agents in real-world analysis. Int J Clin Oncol. 2024;29:213\u201321. https:\/\/doi.org\/10.1007\/s10147-023-02441-8.","journal-title":"Int J Clin Oncol"},{"key":"1230_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102169","volume":"22","author":"F Botelho","year":"2024","unstructured":"Botelho F, Braga I, Le\u00e3o R, Teves F, Dias J, Rodrigues F, et al. Real-life data on first- and second-line treatment of metastatic castration-resistant prostate cancer with abiraterone, enzalutamide and cabazitaxel \u2013 a multicentric study from Portugal. Clin Genitourin Cancer. 2024;22:102169. https:\/\/doi.org\/10.1016\/j.clgc.2024.102169.","journal-title":"Clin Genitourin Cancer"},{"key":"1230_CR64","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/pros.24270","volume":"82","author":"P Vestris","year":"2022","unstructured":"Vestris P, Gourtaud G, Senechal C, Sadreux Y, Roux V, Blanchet P, et al. Overall and progression-free survival of Afro-Caribbean men with metastatic castration-resistant prostate cancer (mCRPC). Prostate. 2022;82:269\u201375. https:\/\/doi.org\/10.1002\/pros.24270.","journal-title":"Prostate"},{"key":"1230_CR65","doi-asserted-by":"publisher","first-page":"3901","DOI":"10.21873\/anticanres.13541","volume":"39","author":"L-W Chang","year":"2019","unstructured":"Chang L-W, Hung S-C, Wang S-S, Li J-R, Yang C-K, Chen C-S, et al. Abiraterone acetate and enzalutamide: similar efficacy in treating post docetaxel metastatic castration-resistant prostate cancer: single center experience. Anticancer Res. 2019;39:3901\u20138. https:\/\/doi.org\/10.21873\/anticanres.13541.","journal-title":"Anticancer Res"},{"key":"1230_CR66","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.euros.2022.04.016","volume":"41","author":"K Izumi","year":"2022","unstructured":"Izumi K, Shima T, Mita K, Kato Y, Kamiyama M, Inoue S, et al. Enzalutamide versus abiraterone plus prednisolone before chemotherapy for castration-resistant prostate cancer: a multicenter randomized controlled trial. Eur Urol Open Sci. 2022;41:16\u201323. https:\/\/doi.org\/10.1016\/j.euros.2022.04.016.","journal-title":"Eur Urol Open Sci."},{"key":"1230_CR67","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1002\/pros.24769","volume":"84","author":"T Tanegashima","year":"2024","unstructured":"Tanegashima T, Shiota M, Tsukahara S, Mutaguch J, Goto S, Kobayashi S, et al. Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration-resistant prostate cancer patients. Prostate. 2024;84:1329\u201335. https:\/\/doi.org\/10.1002\/pros.24769.","journal-title":"Prostate"},{"key":"1230_CR68","doi-asserted-by":"publisher","first-page":"65","DOI":"10.36401\/JQSH-19-39","volume":"3","author":"P Cardoso","year":"2020","unstructured":"Cardoso P, Santos C, Costa F, Rocha-Gon\u00e7alves F. Outcomes management in a real-world evidence context: the case of abiraterone and enzalutamide in the treatment of metastatic castration-resistant prostate cancer. Glob J Qual Saf Healthc. 2020;3:65\u20138. https:\/\/doi.org\/10.36401\/JQSH-19-39.","journal-title":"Glob J Qual Saf Healthc"},{"key":"1230_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2024.102148","volume":"16","author":"CE Gaber","year":"2025","unstructured":"Gaber CE, Okpara E, Abdelaziz AI, Sarker J, Hanson KA, Hassan L, et al. Real-world effectiveness and cardiovascular safety of abiraterone versus enzalutamide amongst older patients diagnosed with metastatic castration-resistant prostate cancer. J Geriatr Oncol. 2025;16:102148. https:\/\/doi.org\/10.1016\/j.jgo.2024.102148.","journal-title":"J Geriatr Oncol."},{"key":"1230_CR70","doi-asserted-by":"publisher","first-page":"4687","DOI":"10.1007\/s00520-020-05311-5","volume":"28","author":"GL Banna","year":"2020","unstructured":"Banna GL, Urzia V, Benanti C, Pitr\u00e8 A, Lipari H, Di Quattro R, et al. Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer. Support Care Cancer. 2020;28:4687\u201395. https:\/\/doi.org\/10.1007\/s00520-020-05311-5.","journal-title":"Support Care Cancer"},{"key":"1230_CR71","doi-asserted-by":"publisher","first-page":"19861","DOI":"10.18632\/oncotarget.24888","volume":"9","author":"JA Gordon","year":"2018","unstructured":"Gordon JA, Buonerba C, Pond G, Crona D, Gillessen S, Lucarelli G, et al. Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study. Oncotarget. 2018;9:19861\u201373. https:\/\/doi.org\/10.18632\/oncotarget.24888.","journal-title":"Oncotarget"},{"key":"1230_CR72","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8081251","volume":"8","author":"K Komura","year":"2019","unstructured":"Komura K, Fujiwara Y, Uchimoto T, Saito K, Tanda N, Matsunaga T, et al. Comparison of radiographic progression-free survival and PSA response on sequential treatment using abiraterone and enzalutamide for newly diagnosed castration-resistant prostate cancer: a propensity score matched analysis from multicenter cohort. J Clin Med. 2019;8:1251. https:\/\/doi.org\/10.3390\/jcm8081251.","journal-title":"J Clin Med"},{"key":"1230_CR73","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3390\/diseases12070162","volume":"12","author":"K Yamaguchi","year":"2024","unstructured":"Yamaguchi K, Kawahara T, Hashizume A, Ousaka K, Uemura K, Ito Y, et al. Enzalutamide prolonged the duration of drug use in comparison to abiraterone acetate and cabazitaxel after upfront docetaxel: a large Japanese database study. Diseases. 2024;12:162. https:\/\/doi.org\/10.3390\/diseases12070162.","journal-title":"Diseases"},{"key":"1230_CR74","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/pros.24796","volume":"85","author":"N Tanaka","year":"2025","unstructured":"Tanaka N, Izumi K, Nakai Y, Shima T, Kato Y, Mita K, et al. Dose modification in enzalutamide and abiraterone plus prednisolone for castration-resistant prostate cancer: A subanalysis from the ENABLE study for PCa. Prostate. 2025;85:21\u20139. https:\/\/doi.org\/10.1002\/pros.24796.","journal-title":"Prostate"},{"key":"1230_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102200","volume":"22","author":"KK Ternov","year":"2024","unstructured":"Ternov KK, Fode M, S\u00f8nksen J, Bisbjerg R, Lindberg H, Palapattu G, et al. Serum androgens as predictive biomarkers: results from a randomized clinical trial comparing enzalutamide and abiraterone acetate in men with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2024;22:102200. https:\/\/doi.org\/10.1016\/j.clgc.2024.102200.","journal-title":"Clin Genitourin Cancer"},{"key":"1230_CR76","doi-asserted-by":"publisher","first-page":"e949","DOI":"10.1093\/oncolo\/oyac147","volume":"27","author":"P Rescigno","year":"2022","unstructured":"Rescigno P, Maruzzo M, Rebuzzi SE, Murianni V, Cinausero M, Lipari H, et al. Adherence to oral treatments in older patients with advanced prostate cancer, the ADHERE study: a prospective trial of the Meet-URO Network. Oncologist. 2022;27:e949\u201356. https:\/\/doi.org\/10.1093\/oncolo\/oyac147.","journal-title":"Oncologist"},{"key":"1230_CR77","doi-asserted-by":"publisher","first-page":"463","DOI":"10.21873\/anticanres.16183","volume":"43","author":"O Fiala","year":"2023","unstructured":"Fiala O, Hosek P, Korunkova H, Hora M, Kolar J, Windrichova J, et al. Enzalutamide or abiraterone acetate with prednisone in the treatment of metastatic castration-resistant prostate cancer in real-life clinical practice: a long-term single institution experience. Anticancer Res. 2023;43:463\u201371. https:\/\/doi.org\/10.21873\/anticanres.16183.","journal-title":"Anticancer Res"},{"key":"1230_CR78","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1007\/s12325-025-03132-8","volume":"42","author":"AS Merseburger","year":"2025","unstructured":"Merseburger AS, Dornstauder E, Ohlmann C-H, Aprikian A, Junker S, Hahn P, et al. Cardiovascular risks and survival with abiraterone vs enzalutamide in chemotherapy-na\u00efve metastatic castration-resistant prostate cancer in Germany: AVENGER study. Adv Ther. 2025;42:1919\u201334. https:\/\/doi.org\/10.1007\/s12325-025-03132-8.","journal-title":"Adv Ther"},{"key":"1230_CR79","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1002\/pros.24923","volume":"85","author":"A Horv\u00e1th","year":"2025","unstructured":"Horv\u00e1th A, Blasszauer C, Komka I, Reibl D, Hadaschik B, Fazekas T, et al. Real-world overall survival comparison of enzalutamide and abiraterone in first- and second-line setting of metastatic castration-resistant prostate cancer. Prostate. 2025;85:1151\u20134. https:\/\/doi.org\/10.1002\/pros.24923.","journal-title":"Prostate"},{"key":"1230_CR80","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/pros.24096","volume":"81","author":"J Liu","year":"2021","unstructured":"Liu J, Lin C, Chen M, Liu K, Lin C, Chen T, et al. Risk of major adverse cardiovascular events among second-line hormonal therapy for metastatic castration-resistant prostate cancer: A real-world evidence study. Prostate. 2021;81:194\u2013201. https:\/\/doi.org\/10.1002\/pros.24096.","journal-title":"Prostate"},{"key":"1230_CR81","doi-asserted-by":"publisher","DOI":"10.1159\/000540864","author":"R Masuda","year":"2024","unstructured":"Masuda R, Noguchi Y, Aizawa H, Yoshizawa S, Nomura Y, Saguchi M, et al. Assessment of cardiovascular events caused by new-generation androgen receptor pathway inhibitors used for prostate cancer: a real-world study in Japan. Oncology. 2025;103(2):134-42. https:\/\/doi.org\/10.1159\/000540864.","journal-title":"Oncology"},{"key":"1230_CR82","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1053\/j.seminoncol.2019.11.004","volume":"46","author":"H Leuva","year":"2019","unstructured":"Leuva H, Sigel K, Zhou M, Wilkerson J, Aggen DH, Park Y-HA, et al. A novel approach to assess real-world efficacy of cancer therapy in metastatic prostate cancer. Analysis of national data on veterans treated with abiraterone and enzalutamide. Semin Oncol. 2019;46:351\u201361. https:\/\/doi.org\/10.1053\/j.seminoncol.2019.11.004.","journal-title":"Semin Oncol"},{"key":"1230_CR83","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1001\/jamaoncol.2024.1549","volume":"10","author":"O El-Taji","year":"2024","unstructured":"El-Taji O, Taktak S, Jones C, Brown M, Clarke N, Sachdeva A. Cardiovascular events and androgen receptor signaling inhibitors in advanced prostate cancer: a systematic review and meta-analysis. JAMA Oncol. 2024;10:874. https:\/\/doi.org\/10.1001\/jamaoncol.2024.1549.","journal-title":"JAMA Oncol"},{"key":"1230_CR84","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41391-024-00886-0","volume":"28","author":"A Matsukawa","year":"2025","unstructured":"Matsukawa A, Yanagisawa T, Parizi MK, Laukhtina E, Klemm J, Fazekas T, et al. Cardiovascular events among men with prostate cancer treated with androgen receptor signaling inhibitors: a systematic review, meta-analysis, and network meta-analysis. Prostate Cancer Prostatic Dis. 2025;28:298\u2013308. https:\/\/doi.org\/10.1038\/s41391-024-00886-0.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1230_CR85","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43:4229\u2013361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244.","journal-title":"Eur Heart J"},{"key":"1230_CR86","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA5006","author":"G Attard","year":"2025","unstructured":"Attard G, Agarwal N, Graff JN, Sandhu S, Efstathiou E, \u00d6zg\u00fcro\u011flu M, et al. Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes. J Clin Oncol. 2025;43(17_Suppl):LBA5006. https:\/\/doi.org\/10.1200\/JCO.2025.43.17_suppl.LBA5006.","journal-title":"J Clin Oncol"},{"key":"1230_CR87","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1038\/s41591-021-01458-8","volume":"27","author":"P Hegyi","year":"2021","unstructured":"Hegyi P, Er\u0151ss B, Izb\u00e9ki F, P\u00e1rniczky A, Szentesi A. Accelerating the translational medicine cycle: the Academia Europaea pilot. Nat Med. 2021;27:1317\u20139. https:\/\/doi.org\/10.1038\/s41591-021-01458-8.","journal-title":"Nat Med"},{"key":"1230_CR88","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.3390\/jcm9051532","volume":"9","author":"P Hegyi","year":"2020","unstructured":"Hegyi P, Petersen OH, Holgate S, Er\u0151ss B, Garami A, Szak\u00e1cs Z, et al. Academia Europaea Position Paper on Translational Medicine: the cycle model for translating scientific results into community benefits. J Clin Med. 2020;9:1532. https:\/\/doi.org\/10.3390\/jcm9051532.","journal-title":"J Clin Med"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01230-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01230-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01230-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T13:15:21Z","timestamp":1785503721000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-026-01230-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":88,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1230"],"URL":"https:\/\/doi.org\/10.1007\/s11523-026-01230-3","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"29 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Boris Hadaschik reports consulting fees from Johnson&Johnson, Bayer, ABX, Astellas, Merck, Amgen, MSD\/Pfizer, Novartis, BMS, Monrol, Onkowissen, POINT Biopharma, Ipsen, AstraZeneca, Lightpoint medical, Telix, and Accord Healthcare; travel support from AstraZeneca, BMS, Janssen, Bayer, Pfizer and Ipsen; grants or contracts from Janssen, Deutsche Forschungsgesellschaft, Novartis, and BMS; participation on data safety monitoring boards for Johnson&Johnson and ABX. Anik\u00f3 Katalin Valikovics, D\u00e1niel Bacs\u00f3, Nadeen Samaien, Isabel Pinto Amorim das Virgens, Bogl\u00e1rka Szentes, Gergely Ag\u00f3cs, Mahmoud Obeidat, Tam\u00e1s Sz\u00e9ll, P\u00e9ter Hegyi, P\u00e9ter Nyir\u00e1dy, and Tibor Szarvas declare that they have no conflicts of interest that might be relevant to the content of this manuscript.","order":1,"name":"Ethics","label":"Conflicts of interest\/Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The datasets used in this study can be found in full-text articles included in this systematic review and meta-analysis, and their supplementary materials.","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.V.: conceptualization, data collection, formal analysis, project administration, visualization, writing\u2014original draft; D.B.: conceptualization, data collection, data curation, formal analysis, writing\u2014review and editing; N.S.: conceptualization, data collection, data curation, formal analysis, writing\u2014review and editing; I.P.A.V.: conceptualization, project administration, methodology, writing\u2014review and editing, supervision; B.Sz.: conceptualization, methodology, formal analysis, visualization, writing\u2014review and editing; G.A.: conceptualization, project administration, methodology, formal analysis, visualization, writing\u2014review and editing; M.O.: conceptualization, project administration, methodology, writing\u2014review and editing; Tam\u00e1s Sz\u00e9ll: conceptualization, writing\u2014review and editing, data curation, supervision; B.H.: conceptualization, writing\u2014review and editing, data curation, supervision; P.H.: conceptualization, writing\u2014review and editing, supervision; P.N.: conceptualization, writing\u2014review and editing, supervision; Tibor Szarvas: conceptualization, writing\u2014review and editing, data curation, project administration, supervision.","order":7,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}